Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-87.37%
0%
-87.37%
6 Months
-91.3%
0%
-91.3%
1 Year
-91.72%
0%
-91.72%
2 Years
-97.13%
0%
-97.13%
3 Years
-99.74%
0%
-99.74%
4 Years
-99.74%
0%
-99.74%
5 Years
-99.82%
0%
-99.82%
Polarean Imaging Plc for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
2.27%
EBIT Growth (5y)
-16.99%
EBIT to Interest (avg)
-8.73
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.99
Sales to Capital Employed (avg)
0.11
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.11
EV to EBIT
-0.15
EV to EBITDA
-0.17
EV to Capital Employed
1.19
EV to Sales
0.60
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-774.23%
ROE (Latest)
-128.79%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bullish
Bollinger Bands
Sideways
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'22
Dec'22
Dec'21
Change(%)
Net Sales
0.80
0.90
-11.11%
Operating Profit (PBDIT) excl Other Income
-10.30
-9.70
-6.19%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-11.30
-10.20
-10.78%
Operating Profit Margin (Excl OI)
-13,233.80%
-12,077.00%
-115.68%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2022 is -11.11% vs 50.00% in Dec 2021
Consolidated Net Profit
YoY Growth in year ended Dec 2022 is -10.78% vs -100.00% in Dec 2021
About Polarean Imaging Plc 
Polarean Imaging Plc
Pharmaceuticals & Biotechnology
Polarean Imaging Plc is a medical drug-devising company. The Company with its subsidiaries operates in the medical imaging market and develops equipment to enable existing magnetic resonance imaging (MRI) systems. The Company focuses on improving the level of pulmonary functional imaging, and specializing the use of polarised Xenon gas (129Xe) as an imaging agent to visualize ventilation, and gas exchange. The Group also develops and manufactures high performance MRI radiofrequency (RF) coils which are a required for imaging 129Xe in the MRI system. The United States food and drug administration (FDA) has accepted the group’s III clinical trial and design.
Company Coordinates 
Company Details
2500 Meridian Pkwy Ste 175 , DURHAM NC : 27713-4214
Registrar Details






